# To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure

## TL;DR

This study finds that MRAs reduce heart failure risks and improve heart function but increase kidney issues, based on a meta-analysis of 30 trials.

## Contribution

A meta-analysis of 30 RCTs provides updated evidence on MRAs' cardiovascular and renal effects in heart failure patients.

## Key findings

- MRAs significantly reduced all-cause and cardiovascular mortality in heart failure patients.
- MRAs improved left ventricular ejection fraction and reduced heart failure hospitalizations.
- MRAs increased risks of hyperkalemia, elevated creatinine, and decreased eGFR.

## Abstract

Mineralocorticoid receptor antagonists (MRAs) are pivotal in heart failure (HF) management.

This study evaluates their impact on adverse cardiovascular events and left ventricular ejection fraction (LVEF) in HF patients.

A comprehensive literature search was conducted across PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials databases, with a cutoff date of September 30, 2024. All included studies were randomized controlled trials (RCTs) that recorded the incidence of adverse cardiovascular events and changes in LVEF after MRA treatment in HF patients.

A total of 30 randomized controlled trials involving 24,831 patients with heart failure were included. Compared to conventional therapy or placebo, treatment with MRAs significantly reduced the risk of all-cause mortality (RR = 0.862, 95% CI: 0.778–0.956, p = 0.005; I2 = 36.1%), cardiovascular mortality (RR = 0.828, 95% CI: 0.732–0.937, p = 0.003; I2 = 45.7%), and heart failure-related hospitalization (RR = 0.780, 95% CI: 0.657–0.926, p = 0.005; I2 = 65.5%). Moreover, MRAs significantly improved LVEF (WMD = 1.384, 95% CI: 0.208–2.559, p = 0.021; I2 = 59.9%). However, MRA therapy was associated with an increased risk of renal dysfunction, including hyperkalemia (RR = 2.086, 95% CI: 1.872–2.325, p < 0.001; I2 = 0.0%), elevated serum creatinine (RR = 1.512, 95% CI: 1.252–1.825, p < 0.001; I2 = 0.0%), decreased eGFR (WMD = −5.223, 95% CI: −7.380 to −3.066, p < 0.001; I2 = 0.0%), and potentially increased incidence of composite renal outcomes.

MRAs significantly reduce the risk of adverse cardiovascular events in patients with heart failure and contribute to LVEF improvement. They lower all-cause mortality in patients with HFrEF and reduce hospitalization for heart failure in those with HFmrEF or HFpEF. However, the potential risk of renal-related adverse events warrants close monitoring.

Our protocol was registered in PROSPERO (registration number: CRD42024592012).